| Patient | Fyodor Dostoevsky |
|---|---|
| Date of birth | 1982-11-11 |
| Identifiers | MRN HR-NI018-SYN; SSN (made up) 000-18-3907 |
| Document date | 2026-05-05 |
| Author | Agnes Lindahl, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Two-month review on lamotrigine, with a trough level. [S]
Mr. Dostoevsky returns nine weeks after starting lamotrigine; he has taken 100 mg twice daily for three weeks. He had one generalized seizure in the third week of the titration, while on 50 mg a day, after a night without sleep to finish a manuscript; a friend who was with him timed it at about two minutes and followed the seizure action plan. He has had none since reaching 150 mg a day. He has had no rash, mouth sores, or fever, and no dizziness or double vision. The sleep-deprived EEG six weeks ago was normal. He has not gambled. He has attended every weekly therapy session and is learning to spot the thoughts that lead him to chase losses. He went to two Gamblers Anonymous meetings and saw the debt counselor, who is drawing up a repayment plan. His mood is better. He has no thoughts of suicide. [S]
| Element | Detail |
|---|---|
| Seizures | One in week three of the titration, after sleep loss; none since |
| Lamotrigine | 100 mg twice daily for three weeks; no rash or other side effects |
| Gambling | None for nine weeks; therapy weekly |
| Mood | PHQ-9 6 |
| System | Result | Finding |
|---|---|---|
| Neurological | Positive | One seizure in week three of the titration; no dizziness, double vision, or unsteadiness |
| Integumentary | Negative | No rash or mouth sores |
| Psychiatric | Negative | Mood better; fewer urges; no thoughts of suicide or self-harm |
3 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Lamotrigine 25 mg tablets, slow titration: 25 mg once daily for weeks 1 and 2, 50 mg once daily for weeks 3 and 4, 50 mg twice daily for week 5, and 75 mg twice daily for week 6 | 25 mg once daily, increased every two weeks and then weekly as written, to 75 mg twice daily in week 6 | Oral route | 2026-03-03 to 2026-04-13 | completed | S |
| Lamotrigine 100 mg tablet, one tablet twice daily | 100 mg twice daily (200 mg a day), 30-day supply at a time | Oral route | 2026-04-14 | active | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 2026-05-05 | Body height | 170 | cm | S |
| 2026-05-05 | Body weight | 68.8 | kg | S |
| 2026-05-05 | Body mass index (BMI) [Ratio] | 23.8 | kg/m2 | S |
| 2026-05-05 | Systolic blood pressure | 118 | mm[Hg] | S |
| 2026-05-05 | Diastolic blood pressure | 76 | mm[Hg] | S |
| 2026-05-05 | Heart rate | 70 | /min | S |
| 2026-05-05 | Respiratory rate | 14 | /min | S |
| 2026-05-05 | Body temperature | 36.7 | Cel | S |
| 2026-05-05 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 2026-05-05 | lamoTRIgine [Mass/volume] in Serum or Plasma | 6.2 | ug/mL | 2.5-15 ug/mL | Normal | S |
| 2026-05-05 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 6 | {score} | S |
Vital signs recorded on 2026-05-05; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Well and relaxed; weight 68.8 kg; blood pressure 118/76, heart rate 70 |
| Skin | No rash on the trunk, limbs, or face |
| Mouth | No ulcers |
| Neurological | No nystagmus or ataxia; tandem gait normal |
| Psychiatric | Euthymic; organized; good insight |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Epilepsy of unknown type with recurrent generalized tonic-clonic seizures of unknown onset, untreated for many years; etiology unknown | active | confirmed | G40.909 | S — Synthetic modern coding of his documented epilepsy. The seizure type is left as unknown onset under the ILAE classification, because the retrospective classifications are disputed; no focal or generalized syndrome is coded. |
| Gambling disorder (roulette, in person and online), moderate, with debts | active | confirmed | F63.0 | S — Synthetic modern coding of his documented compulsive roulette gambling. |
Protocol monitoring: items the monitoring protocol calls for at this visit. [S]
| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Examination | Seizure frequency, seizure diary, and seizure description | Every visit | Completed today | One seizure in week three of the titration after sleep loss; none since reaching 150 mg a day |
| Medication safety | Antiseizure medicine adverse effects (dizziness, double vision, unsteadiness, sleep, mood) | Every visit | Completed today | No dizziness, double vision, unsteadiness, or sleep change |
| Medication safety | Rash and mouth-sore check (lamotrigine) | Every contact during titration and the first two months, then with symptoms | Completed today | No rash or mouth sores |
| Medication safety | Contact at each lamotrigine dose step to check for rash | At each dose increase during titration | Deferred | No contact was scheduled during the six-week titration, a deviation from the plan to check for rash at each dose step. He knew to stop and call for any rash, and none occurred, so no harm resulted. Corrective action: a nurse telephone check at each step of any future titration |
| Medication safety | Adherence and missed doses | Every visit | Completed today | No missed doses; pill organizer and phone alarms |
| Laboratory | Lamotrigine trough level | Once at steady state as a reference, then with breakthrough seizures, suspected nonadherence, or interacting medicines | Completed today | 6.2 ug/mL trough at steady state; recorded as his reference level |
| Imaging | EEG (routine, then sleep-deprived if normal) | At diagnosis | Up to date | Sleep-deprived EEG six weeks ago normal, with no epileptiform discharges |
| Self-management | Trigger review: sleep loss, alcohol, overwork, missed doses | Every visit | Completed today | The titration seizure followed a night without sleep; he now stops writing by midnight |
| Self-management | Seizure safety and driving counseling | At diagnosis and every visit | Completed today | Not driving; precautions followed |
| Self-management | Written seizure action plan for the people around him | At diagnosis, then yearly | Up to date | Used by a friend during the seizure in March |
| Survey | Depression screen (PHQ-9) | At intake, then every two to four months while symptoms are present | Completed today | PHQ-9 6, item 9 scored 0 |
| Survey | Suicide-risk review and safety plan, with the 988 Suicide & Crisis Lifeline | Every visit (gambling disorder and antiseizure-medicine labeling) | Completed today | No thoughts of suicide |
| Survey | Gambling since the last visit: days, money lost, and urges (G-SAS for the past week) | Every visit | Completed today | No gambling for nine weeks; G-SAS 14 for the past week, from urges only |
| Self-management | Cognitive behavioral therapy for gambling disorder | Weekly sessions for at least 8 to 12 weeks, then as needed | Completed today | Weekly, with every session attended |
| Self-management | Self-exclusion from casinos and online gambling | At the start of treatment; renew and extend after any lapse | Up to date | In place |
| Self-management | Financial safeguards (bank gambling block, co-signer for large withdrawals, limited cash) | At the start of treatment | Up to date | Bank block and co-signer in place |
| Referral | Peer support (Gamblers Anonymous) | Offered at the start of treatment and after any lapse | Completed today | Two Gamblers Anonymous meetings attended |
| Referral | Debt counseling | Once, early in treatment | Completed today | Seen; repayment plan being drawn up |
| Medication safety | Medicine for gambling disorder (opioid antagonist) | Considered if psychological treatment alone is not enough | Not indicated | Responding to psychological treatment |
Goal progress:
Guideline basis: Evidence-based guideline: Management of an unprovoked first seizure in adults: Report of the Guideline Development Subcommittee of the American Academy of Neurology and the American Epilepsy Society (2015); Practice guideline update summary: Efficacy and tolerability of the new antiepileptic drugs I: Treatment of new-onset epilepsy (2018); Psychological therapies for pathological and problem gambling (2012); VA/DoD Clinical Practice Guideline for Assessment and Management of Patients at Risk for Suicide (2024); CMID: Clinical Monitoring Intelligence Database, depression, bipolar, and mood disorders monograph (2026)
Follow-up: Four-month review. Call the same day for a rash or a seizure. Next scheduled visit 2026-07-07: four-month review of seizure control, mood, and gambling recovery. [S]